Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2020-04-14 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
对外担保管理制度（2020年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '华邦生命健康股份有限公司 对外担保管理制度' (External Guarantee Management System of Huabang Life Health Co., Ltd.) dated April 2020. It outlines the company's rules, procedures, and responsibilities regarding external guarantees, including approval processes, risk management, disclosure obligations, and accountability. There is no indication that this is a financial report, audit, earnings release, or any form of shareholder meeting material. It is a governance-related document describing internal control and management practices for external guarantees. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2020-04-14 Chinese
关于公司控股子公司山东凯盛新材料股份有限公司上市辅导备案的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Huabang Life Health Co., Ltd. regarding its controlling subsidiary Shandong Kaisheng New Materials Co., Ltd. submitting an application for IPO counseling and filing with the local securities regulatory bureau. It mentions the IPO process and future disclosure obligations but does not contain any financial statements or detailed financial data. The document is only 635 characters long and serves as a notification of a regulatory filing related to IPO preparation. It does not qualify as a full financial report, audit report, or capital update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the IPO counseling filing.
2020-04-13 Chinese
关于公司控股子公司山东凯盛新材料股份有限公司重大事项暂停转让公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Huabang Life Health Co., Ltd. regarding the suspension of trading of its controlling subsidiary Shandong Kaisheng New Materials Co., Ltd. shares due to the planning of a major event, specifically the preparation for an initial public offering (IPO). The announcement explains the reasons for the suspension, the expected timeline, and the uncertainty involved. It does not contain financial statements or detailed financial data but is an update on a capital market event affecting the subsidiary's shares. The document is short (925 characters) and serves as a regulatory announcement about a capital market event rather than a full financial report or detailed management discussion. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-09 Chinese
关于董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Wang Jiarong, from the board and the strategic committee. It discusses the resignation date, legal compliance, and the impact on the board's operation. There is no financial data, no mention of financial results, no report publication, or any other type of report. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2020-04-09 Chinese
关于归还用于暂时补充流动资金的部分闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (643 characters) regarding the return of temporarily used idle raised funds to the dedicated account. It references a previous announcement about the use of idle raised funds for working capital and confirms the completion of the return. There are no financial statements or detailed financial data presented, only a status update on the use and return of funds. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's financing activities and capital usage. The document is not a full report, nor an announcement of a report publication, but a specific update on capital usage.
2020-04-01 Chinese
关于全资子公司药品阿那曲唑片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Huabang Life Health Co., Ltd. regarding its wholly-owned subsidiary's drug Anastrozole tablets passing the generic drug consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, impact on the company, and risk warnings. The document is short (1103 characters) and serves as a regulatory announcement about a product approval and its implications, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and company impact.
2020-03-20 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.